CCK and Fabry disease: Moreover, administration of the CCK-A receptor antagonist, dexloxiglumide, reduced nausea, bloating and fullness, induced by duodenal lipid infusion, in patients [82], providing evidence that CCK mediates, at least in part, the effects of fat on symptoms in FD.